Stoke Therapeutics, Inc. (STOK)
NASDAQ: STOK · Real-Time Price · USD
19.76
-0.01 (-0.05%)
At close: Aug 29, 2025, 4:00 PM
20.01
+0.25 (1.27%)
After-hours: Aug 29, 2025, 7:57 PM EDT
Stoke Therapeutics Employees
Stoke Therapeutics had 128 employees as of December 31, 2024. The number of employees increased by 18 or 16.36% compared to the previous year.
Employees
128
Change (1Y)
18
Growth (1Y)
16.36%
Revenue / Employee
$1,561,664
Profits / Employee
$410,039
Market Cap
1.08B
Employees Chart
Employees History
Date | Employees | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 128 | 18 | 16.36% |
Dec 31, 2023 | 110 | -7 | -5.98% |
Dec 31, 2022 | 117 | 15 | 14.71% |
Dec 31, 2021 | 102 | 23 | 29.11% |
Dec 31, 2020 | 79 | 23 | 41.07% |
Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
Company Name | Employees |
---|---|
UnitedHealth Group | 400,000 |
Johnson & Johnson | 138,100 |
Thermo Fisher Scientific | 125,000 |
Abbott Laboratories | 114,000 |
AstraZeneca | 92,900 |
Novo Nordisk | 77,349 |
Novartis AG | 75,883 |
Merck & Co. | 75,000 |
STOK News
- 2 days ago - Stoke Therapeutics to Present at Upcoming Investor Conferences in September 2025 - Business Wire
- 5 days ago - Stoke Therapeutics and Biogen Announce Presentations of Clinical Data from Studies of Zorevunersen for the Potential Treatment of Dravet Syndrome at the 36th International Epilepsy Congress - Business Wire
- 12 days ago - Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) - Business Wire
- 18 days ago - Stoke Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Updates - Business Wire
- 19 days ago - Stoke Therapeutics and Biogen Announce First Patient Dosed in Phase 3 EMPEROR Study of Zorevunersen, a Potential Disease-Modifying Treatment for Dravet Syndrome - Business Wire
- 23 days ago - Stoke Therapeutics to Host Webcast and Conference Call to Discuss Second Quarter 2025 Business and Financial Updates - Business Wire
- 24 days ago - Stoke Therapeutics to Present at the Canaccord Genuity 45th Annual Growth Conference - Business Wire
- 6 weeks ago - Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire